ClinicalTrials.gg
Active, not recruitingNCT02402660TEASEUpdated Sep 21, 2026

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

A Phase 2 interventional study of ALK-001 and Placebo in Stargardt Disease, Stargardt Macular Degeneration and Stargardt Macular Dystrophy, sponsored by Alkeus Pharmaceuticals, Inc.. Active, not recruiting at 14 sites in United States. Open to participants aged 8 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Alkeus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
8 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.

Planned enrollment
6th of 26
160 · median 41
Started
2015
the only one that year
Phase 2
7 of 42
none open now
Primary completion
2028-06
later than 11 of 24 live
Registered
11th of 42
by date
Lead sponsor
3 of 42
Alkeus Pharmaceuticals, Inc.

Among the 42 studies in Stargardt Disease with a site in United States, this one is the 6th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2015, is one of 7 in phase 2, reaches primary completion later than 11 of the 24 other live ones, and was the 11th registered.

Stargardt Disease

66 studies on the registry are indexed under Stargardt Disease; 25 are open to participants now.

Browse Stargardt Disease studies →

Open to participants now

16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Stargardt Disease studies recruiting now, 14 (64%) set no upper age limit and 7 (32%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 8 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Stargardt Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old.

Funding Source - FDA OOPD

Read the detailed description

This study evaluates the effects of orally-administered ALK-001 on the progression of Stargardt disease (ABCA4-related). Stargardt disease is a rare genetic disorder that leads to damage to the retina and results in legal blindness. Stargardt disease is caused by a defective ABCA4 gene, which affects the processing of vitamin A in the eye and leads to the formation of toxic vitamin A aggregates (called "vitamin A dimers") in the eye. Vitamin A dimers are thought to contribute to vision loss in Stargardt disease. ALK-001, the investigational drug, is a chemically-modified vitamin A designed as a replacement of vitamin A to prevent the formation of toxic vitamin A dimers in the eye. Trial participants will receive either ALK-001 or placebo, and follow-up visits will take place periodically for up to 24 months. There is currently no treatment for Stargardt disease.

03

Conditions studied

  • Stargardt Disease
  • Stargardt Macular Degeneration
  • Stargardt Macular Dystrophy
  • Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

Browse trials for

04

Who can participate

Ages eligible
8 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Simplified Inclusion Criteria:

  • Male or female between 8 and 70 years old (inclusive), with any visual acuity
  • Has a clinical diagnosis of typical autosomal recessive Stargardt macular dystrophy (STGD1)
  • Has provided a genetic report indicating at least two ABCA4 disease-causing mutations. When only one ABCA4 disease-causing mutation is reported, sponsor's permission will be required.
  • At least one eye (called the "primary study eye") must have at least one well-demarcated area of significantly reduced autofluorescence as imaged by fundus autofluorescence (FAF), have decreased retinal sensitivity as measured by microperimetry, or have maculopathy expected to progress over the duration of the study
  • Primary study eye must have clear ocular media and adequate pupillary dilation, including no allergy to dilating eyedrops, to permit good quality retinal imaging
  • Healthy as judged by investigator
  • Able and willing to comply with study requirements, restrictions and instructions and is likely to complete the 24-month study
  • Has signed and dated the forms (or assent where appropriate) to participate
  • Female of has signed the informed consent about birth defects or attestation on requirements

Main Exclusion Criteria:

  • Has taken disallowed items (supplement containing vitamin A or beta-carotene, liver-based products, or prescription oral retinoid medications) over the past 30 days
  • Is lactating, pregnant, or has a positive serum or urine pregnancy test at screening or at randomization
  • Has concurrent medical condition or history, which in the opinion of the investigator, is likely to prevent compliance with the protocol and/or interfere with absorption of ALK-001 or study procedures
  • Has abnormal laboratory result(s) at screening
  • Has active or historical acute or chronic liver disorder
  • Has active or historical ocular disorder in the primary study eye that, in the opinion of the investigator, may confound assessment of the retina morphologically or functionally (this could include for example cataract surgery within the past 6 months, choroidal neovascularization (CNV), glaucoma, recurring uveitis, diabetic retinopathy, other retinal disease, etc.)
  • Has had intraocular surgery or injections in the primary study eye within 90 days of the screening visit
  • Has a clinically significant abnormal (ECG), or has a interval (QTc) that is 450 ms or greater
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    ALK-001

    Daily, oral administration of one capsule. See details below.

    Drug: ALK-001

  • Placebo comparator
    Placebo

    Daily, oral administration of one capsule. See details below.

    Drug: Placebo

Interventions

  • Daily, oral administration for 24 months

    Also known as: C20-D3-Retinyl Acetate, C20 Deuterated vitamin A

  • DrugPlacebo

    Daily, oral administration for 24 months

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of 24 months of daily dosing of ALK-001 assessed by incidence and/or clinically significant changes of a combination of ocular and non-ocular adverse events

    Time frame: From baseline to 24 months

Secondary outcomes

  1. Effects of ALK-001 on the progression of Stargardt disease

    Combination of changes in atrophic lesion size, best corrected visual acuity (BCVA), and ocular assessments.

    Time frame: From baseline to 24 months

  2. Pharmacokinetic profile of ALK-001 derived from the concentrations of ALK-001 and metabolites in plasma

    Time frame: Up to 24 months

07

Study locations

14 sites
  • Alkeus Site
    Phoenix, Arizona 85020, United States
  • Alkeus Site
    Los Angeles, California 90095, United States
  • Alkeus Site
    Aurora, Colorado 80045, United States
  • Alkeus Site
    Gainesville, Florida 32601, United States
  • Alkeus Site
    Miami, Florida 33136, United States
  • Alkeus Site
    Indianapolis, Indiana 46202, United States
  • Alkeus Site
    Baltimore, Maryland 21287, United States
  • Alkeus Site
    Grand Rapids, Michigan 49546, United States
  • Alkeus Site
    New York, New York 10032, United States
  • Alkeus Site
    Westbury, New York 11590, United States
  • Alkeus Site
    Houston, Texas 77025, United States
  • Alkeus Site
    Salt Lake City, Utah 84132, United States
  • Alkeus Site
    Silverdale, Washington 98383, United States
  • Alkeus Site
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Publications

  • Ma L, Kaufman Y, Zhang J, Washington I. C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease. J Biol Chem. 2011 Mar 11;286(10):7966-7974. doi: 10.1074/jbc.M110.178657. Epub 2010 Dec 14. PubMed 21156790 ↗
  • Kaufman Y, Ma L, Washington I. Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents. J Biol Chem. 2011 Mar 11;286(10):7958-7965. doi: 10.1074/jbc.M110.178640. Epub 2010 Nov 12. PubMed 21075840 ↗
  • Mihai DM, Jiang H, Blaner WS, Romanov A, Washington I. The retina rapidly incorporates ingested C20-D(3)-vitamin A in a swine model. Mol Vis. 2013 Jul 25;19:1677-83. Print 2013. PubMed 23914132 ↗
  • Charbel Issa P, Barnard AR, Herrmann P, Washington I, MacLaren RE. Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization. Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8415-20. doi: 10.1073/pnas.1506960112. Epub 2015 Jun 23. PubMed 26106163 ↗
  • Saad L, Washington I. Can Vitamin A be Improved to Prevent Blindness due to Age-Related Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies? Adv Exp Med Biol. 2016;854:355-61. doi: 10.1007/978-3-319-17121-0_47. PubMed 26427432 ↗
  • Zhang D, Robinson K, Washington I. C20D3-Vitamin A Prevents Retinal Pigment Epithelium Atrophic Changes in a Mouse Model. Transl Vis Sci Technol. 2021 Dec 1;10(14):8. doi: 10.1167/tvst.10.14.8. PubMed 34878528 ↗
  • Zhang D, Robinson K, Saad L, Washington I. Vitamin A cycle byproducts impede dark adaptation. J Biol Chem. 2021 Sep;297(3):101074. doi: 10.1016/j.jbc.2021.101074. Epub 2021 Aug 12. PubMed 34391781 ↗
  • Kay CN, Saad L, DeBartolomeo G, Bressler N, Tsang SH, Stepien K, Bernstein P, Lam BL, Washington I, Gorin MB; TEASE-1 Study Group. Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: The TEASE-1 Randomized Clinical Trial. JAMA Ophthalmol. 2026 Sep 3:e263662. doi: 10.1001/jamaophthalmol.2026.3662. Online ahead of print. PubMed 42690655 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2015 (actual). Primary completion is estimated for Jun 2028, 154 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2015
First posted
Mar 30, 2015
StartActual
Aug 2015
Primary completionEst.
Jun 30, 2028
CompletionEst.
Nov 30, 2028
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02402660
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Mar 30, 2015
Start date
Aug 2015
Primary completion
Jun 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Sep 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gildeuretinol acetate

Start the discussion